All In Biotech

Drug Trial Radar · NCT05086107

Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of BV100 Administered as Single Intravenous In-fusion to Subjects With Renal Impairment

Last checked: Nov 19, 2026Latest source record: Jan 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Oct 8, 2021

Primary completion

May 30, 2022

Study completion Jan 16, 2023

Sponsor

Lead sponsor
BioVersys AGIndustry
Sponsor type
Industry
Collaborators
Clinical Research Units Hungary
First posted
Oct 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100

Conditions

  • Renal Impairment

Interventions

  • BV100Drug

    Rifabutin for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairmentTime frame: 96 hours
  2. To characterize the single dose pharmacokinetic profile of rifabutinTime frame: 96 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRU Hungary Kft., Early Phase Unit

    Miskolc, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.